Explore the latest clinical research, innovative therapies, and emerging treatment strategies transforming the management of atopic dermatitis and psoriasis. From biologics and nanoformulations to regenerative and combination therapies, stay updated with evidence-based dermatology insights in 2026.
Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory skin disorder characterized by dry, scaly lesions, erythema, and intense pruritus. Beyond cutaneous manifestations, it involves systemic inflammation, skin barrier dysfunction, and immune dysregulation. Core management includes consistent skin care and trigger avoidance, supplemented by pharmacologic therapy when needed. While corticosteroids and immunosuppressants were traditionally central to treatment, newer targeted therapies now provide more precise disease control with reduced reliance on steroids.
Read MoreThis 12-week randomized, single-blind trial conducted in Central Luzon, Philippines, evaluated adjunctive Saba banana (Musa × paradisiaca) leaf wraps plus petroleum jelly versus petroleum jelly alone in 60 adult farm workers with mild-to-moderate plaque psoriasis (PASI 5–15). Compared with emollient monotherapy, the combination therapy produced significantly greater reductions in PASI scores (mean difference −4.8; 95% CI: −5.9 to −3.7; p<0.001), greater improvements in Dermatology Life Quality Index scores (65% vs. 32%; p<0.01), and larger decreases in pruritus visual analog scale scores (72% vs. 41%; p<0.01). No serious adverse events were observed, with only mild transient erythema reported in three participants. These findings indicate that banana leaf wraps may serve as a safe, low-cost adjunctive strategy for improving psoriasis severity and patient-reported outcomes in resource-limited settings.
Read MoreEli Lilly and Company announced that its weight-loss therapy Zepbound, when used in combination with the psoriasis biologic Taltz, demonstrated superior efficacy compared with Taltz monotherapy in a late-stage clinical trial involving 274 patients with psoriasis and obesity; at 36 weeks, 27.1% of patients receiving the combination achieved complete skin clearance along with at least 10% weight reduction, compared with 5.8% of those treated with Taltz alone, thereby meeting the primary study endpoint and indicating enhanced dermatologic improvement with concurrent weight loss.
Read MorePsoriasis remains challenging to treat due to chronic inflammation and poor penetration of conventional topical agents. Although herbal bioactives possess anti-inflammatory and immunomodulatory properties, their clinical utility is limited by low solubility and stability. Nanocarrier systems—such as liposomes and solid lipid or polymeric nanoparticles—enhance skin penetration, retention, and controlled release, improving therapeutic efficacy while reducing adverse effects. Incorporation of herbal nanoformulations into topical therapies represents a promising, biocompatible strategy for more effective psoriasis management.
Read MorePsoriasis is a chronic autoimmune skin disease affecting about 2.3% of the global population and significantly impairing quality of life. Its pathogenesis involves genetic susceptibility, environmental triggers, and immune dysregulation. Although conventional therapies—including topical agents, systemic drugs, biologics, and phototherapy—are effective, they may be limited by adverse effects and suboptimal targeting. Nanocarrier-based drug delivery systems, particularly lipid- and polymer-based platforms, offer improved skin penetration, targeted action, and reduced toxicity. This review outlines psoriasis pathogenesis, current treatments, and emerging nanotechnology-driven therapeutic approaches.
Read MorePsoriasis management is often limited by adverse effects and poor adherence associated with conventional therapies. This study developed a curcumin-loaded solid lipid nanoparticle (CUR-SLN) nanogel to enhance topical delivery and therapeutic efficacy. Optimized nanoparticles (~134 nm; entrapment efficiency ~89%) were incorporated into a Carbopol-based gel and evaluated for physicochemical properties, drug release, skin permeation, and stability. Compared with conventional curcumin gel, the CUR-SLN nanogel demonstrated sustained release over 48 hours and significantly improved skin permeation and retention. In a psoriasis-induced mouse model, the formulation markedly reduced disease severity and significantly downregulated pro-inflammatory cytokines (IFN-α, IL-23, IL-17, TNF-α; p < 0.001), with histological evidence of restored skin architecture. These findings suggest that the CUR-SLN nanogel is a promising and potentially safer topical strategy for psoriasis management.
Read MoreAtopic dermatitis (AD) is a chronic inflammatory skin disorder marked by barrier dysfunction and immune dysregulation, with significant quality-of-life impact. Conventional treatments provide symptomatic relief but may have limited long-term efficacy and adverse effects. Emerging evidence from in vitro models suggests that secretome-based therapy can reduce inflammation, promote keratinocyte regeneration, and restore skin barrier integrity. By targeting underlying pathogenic mechanisms, the secretome represents a promising non-invasive strategy for improved AD management.
Read MoreAtopic dermatitis (AD) is a chronic inflammatory skin disease with substantial physical and psychosocial burden. Despite established treatment guidelines, real-world care is often hindered by delayed diagnosis, misinformation, financial constraints, poor adherence, and fragmented care. Although advances in topical, systemic, and biologic therapies have improved management, barriers such as steroid hesitancy and limited access persist. Proactive management, timely specialist referral, teledermatology, and patient education are essential to enhance long-term disease control and quality of life.
Read MoreThis study assessed the addition of a soothing moisturizing repair cream to topical fluticasone in children (6–12 years) with moderate atopic dermatitis. Compared with fluticasone alone, combination therapy achieved higher clinical efficacy (100% vs. 84%, P = .040), reduced recurrence rates, and prolonged remission, with both groups showing improved quality-of-life scores. The results support adjunctive moisturizer use to enhance outcomes and decrease relapse risk in pediatric AD.
Read MoreImpaired skin barrier function in atopic dermatitis (AD) increases cutaneous exposure to environmental and food antigens, contributing to the higher prevalence of food allergies in affected individuals. The dual allergen exposure hypothesis suggests that while early oral exposure promotes immune tolerance, transcutaneous exposure activates the T helper 2 pathway and facilitates allergic sensitization. Emerging evidence also indicates that effective control of AD may reduce the risk of food allergy development. These findings raise concerns about the use of food-derived ingredients in topical products, such as moisturizers commonly used in AD management, although many such ingredients exhibit low allergenic potential. This discrepancy highlights the need to better understand why certain antigens induce sensitization while others remain clinically benign.
Read MoreEnvironmental stressors disrupt the skin barrier, worsening dryness and inflammatory conditions such as atopic dermatitis, acne, and psoriasis. Effective repair requires optimal hydration and restoration of the ceramide–cholesterol–fatty acid ratio (3:1:1). Unlike conventional moisturizers that mainly provide surface hydration, next-generation formulations incorporate bioactive ingredients to enhance barrier repair, modulate inflammation, and support skin homeostasis. Oryza Ceramax, a ceramide-dominant formulation with aquaporin boosters and additional actives, reflects this multi-pathway approach. Although evidence supports ceramide-based products in reducing transepidermal water loss and improving hydration, further independent clinical validation is needed.
Read MoreThis double-blind randomized controlled trial evaluated the efficacy of topical ivermectin 1% cream versus ketoconazole 2% cream in 36 patients with facial seborrheic dermatitis (SD). Over two months, both treatments significantly improved Seborrheic Dermatitis Area and Severity Index (SEDASI) scores, erythema index, pruritus severity, and Dermatology Life Quality Index (DLQI) scores (p < 0.001). However, no significant differences were observed between groups in clinical or quality-of-life outcomes. These findings indicate that topical ivermectin is a safe and effective alternative to ketoconazole for facial SD and may be incorporated into the therapeutic armamentarium.
Read MorePerioral dermatitis is an inflammatory facial eruption presenting with erythematous papules or pustules that typically spare the vermilion border. Although more common in young women, it can occur in older adults, where it often follows a prolonged, relapsing course and is frequently misdiagnosed. Topical or inhaled corticosteroids are the most consistent triggers, with additional contributors including fluoride toothpaste, cosmetics, occlusive products, continuous positive airway pressure masks, repetitive lip contact, and age-related barrier impairment. Diagnosis is clinical and requires exclusion of rosacea, seborrheic dermatitis, and contact dermatitis. Management involves withdrawal of corticosteroids and irritants, topical nonsteroidal anti-inflammatory agents, and oral tetracyclines for refractory cases, with early recognition and patient education essential to prevent relapse.
Read MoreThis prospective pilot study evaluated the efficacy and safety of intradermal polynucleotide (PN) injections for facial erythema and barrier dysfunction in 19 adults with mild-to-moderate atopic dermatitis. Participants received three treatment sessions at 3-week intervals, with assessments through week 10. Significant improvements were observed in transepidermal water loss, skin hydration, erythema index, and Investigator Global Assessment scores (all p < 0.01), while skin elasticity showed non-significant favorable trends. Patient satisfaction improved, and no serious adverse events occurred. These findings suggest that intradermal PN therapy may be a safe and beneficial option for managing facial erythema and barrier impairment in adult AD.
Read MoreThis open-label extension trial (INTEGUMENT-OLE; NCT04804605) evaluated the long-term safety and efficacy of roflumilast cream 0.15% in 657 patients aged ≥6 years with atopic dermatitis who completed prior phase 3 studies. Over up to 52 weeks of treatment, 36.7% reported adverse events, with 4.7% considered treatment related; application site discomfort was infrequent. Patients achieving clear skin (vIGA-AD 0) after 4 weeks transitioned to twice-weekly proactive application, maintaining clear or almost clear status for a median of 281 days. These findings indicate that roflumilast cream is well tolerated long term and that proactive twice-weekly use effectively sustains clinical improvement in AD.
Read MoreThis prospective, open-label randomized trial compared 1% benvitimod cream with halometasone in 64 patients with moderate-to-severe chronic hand eczema. After 8 weeks of treatment and 12-week evaluation, treatment success rates were comparable between benvitimod (26.7%) and halometasone (24.1%) groups (p = 0.824), with significant improvements in Hand Eczema Severity Index and patient-reported quality-of-life scores in both groups (p < 0.05), without between-group differences. Relapse at week 24 occurred in 25.0% of benvitimod-treated and 57.1% of halometasone-treated responders (p=0.315). Adverse events with benvitimod were mild and did not require discontinuation. Overall, benvitimod demonstrated efficacy and safety comparable to halometasone, with a low relapse rate in moderate-to-severe chronic hand eczema.
Read MorePsoriasis symptoms often fluctuate, and while initiating a new therapy can promote skin healing and symptom control, visible improvement may take time. Recognizing early indicators of treatment response—alongside objective assessments by a dermatologist—helps determine therapeutic effectiveness. Through ongoing evaluation and collaboration, patients and clinicians can optimize management strategies to achieve sustained disease control and clearer skin.
Read MoreOver the past two decades, psoriasis treatment has expanded considerably, providing more effective options for this chronic inflammatory disorder affecting 2–3% of the global population. Optimal management requires a comprehensive strategy that addresses cutaneous symptoms, underlying immune dysregulation, and quality-of-life burden. This evidence-based overview outlines current therapeutic modalities—including topical agents, phototherapy, and biologics—along with key triggers, complications, and integrated management approaches.
Read MoreChronic hand eczema is a persistent inflammatory condition with significant occupational and psychosocial burden and is often misdiagnosed as atopic dermatitis. A panel of French experts developed a practical, stepwise treatment algorithm based on updated diagnostic criteria, disease subtypes, and severity. The guidance emphasizes accurate assessment, prevention through irritant and allergen avoidance, and the role of targeted therapies in moderate-to-severe cases to improve real-world management and outcomes.
Read MoreThis retrospective study using the JMDC Claims database evaluated 244,316 children aged 0–6 years with atopic dermatitis (AD) between 2018 and 2023. Most patients (82.3%) had coexisting allergic comorbidities (ACMs), primarily allergic rhinitis. Compared with AD-only cases, children with ACMs more frequently received potent topical corticosteroids, systemic steroids, and antihistamines, had more outpatient visits, and incurred substantially higher annual healthcare costs (139,391 vs. 98,646 Yen), with costs rising as the number of ACMs increased. These findings demonstrate the significant added clinical and economic burden of ACMs in pediatric AD, underscoring the need for more intensive management and healthcare resource allocation.
Read More